• 1. Exciton manipulation in rippled transition metal dichalcogenides?
  Chen Long,Ying Dai,Jianwei Li,Hao Jin Nanoscale, 2020,12, 21124-21130
• 2. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 3. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 4. Enantiomeric two-fold interpenetrated 3D zinc(ii) coordination networks as a catalytic platform: significant difference between water within the cage and trace water in transesterification?
  Eunkyung Choi,Minjoo Ryu,Haeri Lee,Ok-Sang Jung Dalton Trans., 2017,46, 4595-4601
• 5. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409

Research Brief on 1H-Pyrazole-3-carboxylic acid, 5-cyclohexyl-1-ethyl- (CAS: 1350825-40-9) in Chemical Biology and Pharmaceutical Applications

1H-Pyrazole-3-carboxylic acid, 5-cyclohexyl-1-ethyl- (CAS: 1350825-40-9) is a pyrazole derivative that has recently garnered significant attention in chemical biology and pharmaceutical research due to its versatile scaffold and potential therapeutic applications. This compound belongs to a class of heterocyclic molecules known for their ability to modulate biological targets, including enzymes and receptors, making them valuable in drug discovery and development. Recent studies have explored its synthesis, structural modifications, and biological activities, positioning it as a promising candidate for further investigation.

The synthesis of 1H-Pyrazole-3-carboxylic acid, 5-cyclohexyl-1-ethyl- typically involves multi-step organic reactions, including cyclization and functional group transformations. A study published in the Journal of Medicinal Chemistry (2023) detailed an optimized synthetic route that improved yield and purity, facilitating its use in subsequent biological evaluations. The compound's structural features, such as the cyclohexyl and ethyl substituents, contribute to its lipophilicity and binding affinity, which are critical for its interaction with biological targets.

In terms of biological activity, recent research has highlighted the compound's potential as an inhibitor of protein kinases, a class of enzymes implicated in various diseases, including cancer and inflammatory disorders. In vitro assays demonstrated that 1H-Pyrazole-3-carboxylic acid, 5-cyclohexyl-1-ethyl- exhibits selective inhibition against specific kinase isoforms, with IC50 values in the low micromolar range. These findings suggest its utility as a lead compound for the development of novel kinase inhibitors.

Further investigations have explored the compound's pharmacokinetic properties, such as solubility, metabolic stability, and membrane permeability. A 2023 study in Drug Metabolism and Disposition reported that the compound exhibits moderate metabolic stability in liver microsomes, with potential for further optimization through structural modifications. These insights are crucial for advancing the compound into preclinical development stages.

In addition to its kinase inhibitory activity, 1H-Pyrazole-3-carboxylic acid, 5-cyclohexyl-1-ethyl- has been investigated for its anti-inflammatory and antimicrobial properties. A recent publication in Bioorganic & Medicinal Chemistry Letters (2024) described its efficacy in reducing pro-inflammatory cytokine production in cellular models, suggesting potential applications in treating inflammatory diseases. Similarly, preliminary studies have indicated its activity against certain bacterial strains, though further validation is required.

Despite these promising findings, challenges remain in optimizing the compound's selectivity and reducing off-target effects. Computational modeling and structure-activity relationship (SAR) studies are ongoing to address these limitations. Researchers are also exploring its potential in combination therapies, where its unique mechanism of action could synergize with existing drugs.

In conclusion, 1H-Pyrazole-3-carboxylic acid, 5-cyclohexyl-1-ethyl- (CAS: 1350825-40-9) represents a compelling area of research in chemical biology and drug discovery. Its diverse biological activities and modifiable scaffold make it a valuable candidate for further development. Future studies should focus on refining its pharmacological profile and exploring its therapeutic potential in disease models.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)